Cancer immunotherapy by PD-1 blockade (Homo sapiens)
From WikiPathways
Description
Immune checkpoints are hardwired into the immune system and are crucial for maintaining self-tolerance. Tumors can use these checkpoints to protect themselves from immune system attacks.
One such immune checkpoint is PD-1 (programmed cell death 1 protein), which binds to its ligand PD-L1 and inhibits immune cell activity, including T cell activity. By upregulating PD-L1, cancer cells can inhibit T cells that might otherwise attack. One strategy for cancer immunotherapy is to block this kind of negative feedback, thereby increasing anti-cancer T-cell activity. For the PD-1 checkpoint, cancer immunotherapeutics block either the PD-1 receptor, or the PD-L1 ligand. The 2018 Nobel prize in Physiology or Medicine was awarded to jointly to James Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.
Based on and figure 4B in the review by Pardoll and figure 1 in the review by Sharpe and Pauken.
Quality Tags
Ontology Terms
Saving...Bibliography
View all... |
- Sharpe AH, Pauken KE; ''The diverse functions of the PD1 inhibitory pathway.''; Nat Rev Immunol, 2018 PubMed Europe PMC Scholia
- Pardoll DM; ''The blockade of immune checkpoints in cancer immunotherapy.''; Nat Rev Cancer, 2012 PubMed Europe PMC Scholia
- Syed YY; ''Durvalumab: First Global Approval.''; Drugs, 2017 PubMed Europe PMC Scholia
- Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; ''Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.''; N Engl J Med, 2018 PubMed Europe PMC Scholia
- Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P; ''Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.''; J Immunother Cancer, 2018 PubMed Europe PMC Scholia
- Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E; ''PhosphoSitePlus, 2014: mutations, PTMs and recalibrations.''; Nucleic Acids Res, 2015 PubMed Europe PMC Scholia
- Sadreddini S, Baradaran B, Aghebati-Maleki A, Shanehbandi D, Fotouhi A, Aghebati-Maleki L; ''Immune checkpoint blockade opens a new way to cancer immunotherapy.''; J Cell Physiol, 2019 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
| View all... |
| Name | Type | Database reference | Comment |
|---|---|---|---|
| AMP-224 | Metabolite | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-fusion-protein-amp-224 | |
| Atezolizumab | Metabolite | Q20707748 (Wikidata)  | |
| Avelumab | Metabolite | Q21083261 (Wikidata) | |
| BATF | GeneProduct | ENSG00000156127 (Ensembl) | |
| CD274 | GeneProduct | ENSG00000120217 (Ensembl) | |
| CD3D | GeneProduct | ENSG00000167286 (Ensembl) | |
| CD3E | GeneProduct | ENSG00000198851 (Ensembl) | |
| CD3G | GeneProduct | ENSG00000160654 (Ensembl) | |
| CD8A | GeneProduct | ENSG00000153563 (Ensembl) | |
| CD8B | GeneProduct | ENSG00000172116 (Ensembl) | |
| Durvalumab | Metabolite | Q19904005 (Wikidata) | |
| IFNG | GeneProduct | ENSG00000111537 (Ensembl) | |
| JUN | GeneProduct | ENSG00000177606 (Ensembl) | |
| LCK | GeneProduct | ENSG00000182866 (Ensembl) | |
| MDX-1105 | Metabolite | ||
| MHC I | Protein | ENSG00000206503 (Ensembl) | |
| MHC II | Protein | ENSG00000196126 (Ensembl) | |
| NF-kB | GeneProduct | ||
| NFAT | GeneProduct | ||
| Nivolumab | Metabolite | Q7041828 (Wikidata) | |
| PDCD1 | GeneProduct | ENSG00000188389 (Ensembl) | |
| PDCD1LG2 | GeneProduct | ENSG00000197646 (Ensembl) | |
| PI3K signaling | Pathway | WP4172 (WikiPathways) | |
| PTPN11 | GeneProduct | ENSG00000179295 (Ensembl) | |
| Pembrolizumab | Metabolite | Q13896859 (Wikidata) | |
| Pidilizumab | Metabolite | Q7191298 (Wikidata) | |
| Ras signaling | Pathway | WP4223 (WikiPathways) | |
| STAT3 | GeneProduct | ENSG00000168610 (Ensembl) | |
| TRA | GeneProduct | 6955 (Entrez Gene) | |
| TRB | GeneProduct | 6957 (Entrez Gene) | |
| Tislelizumab | Metabolite | D11487 (KEGG Drug) | |
| Tumor-associated antigen | GeneProduct | ||
| ZAP70 | GeneProduct | ENSG00000115085 (Ensembl) |
Annotated Interactions
No annotated interactions
